文献速递泌尿生殖MRUS

根据病灶大小和PSA密度在MRI引导活检路径中比较前列腺活检策略

Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway.
PubMed 文献 · Abdom Radiol (NY) · 2020-07-31

该回顾性研究纳入313例接受MRI及系统活检和MRI靶向活检的男性,比较不同指数病灶大小下经直肠超声可见性及饱和活检和系统活检的附加价值,并按现行指南比较四种活检策略的临床显著前列腺癌检出率和需活检比例。病灶<10 mm时超声不可见比例更高(42.7% vs 20.0%,p<0.001),饱和活检和系统活检附加价值更高(11.1%和17.1% vs 4.2%和6.3%)。在MRI不可疑时以PSA密度>0.15 ng/mL/mL为阈值可使需活检人数减少14%(44/313)。

要点

  • 病灶<10 mm时超声不可见比例42.7%,显著高于病灶≥10 mm的20.0%(p<0.001)。
  • 病灶<10 mm时饱和活检和系统活检附加价值分别为11.1%和17.1%,高于≥10 mm的4.2%和6.3%。
  • MRI不可疑时以PSA密度>0.15 ng/mL/mL为阈值可使需活检人数减少14%(44/313)。

核心结论

  • 确定活检策略(是否需要饱和活检或系统活检)时应考虑病灶大小。
  • 在MRI不可疑时使用PSA密度可减少需活检的男性人数。

研究设计与样本

  • 回顾性研究,纳入2019年4月至2020年2月间连续接受MRI及后续系统活检和MRI靶向活检的可疑病灶男性313例。
  • 中位年龄65岁(四分位距60‒71岁)。
  • 比较经直肠超声病灶可见性及饱和活检和系统活检的附加价值(按病灶大小分组,使用卡方检验和McNemar检验)。
  • 基于现行指南比较四种活检策略的临床显著前列腺癌检出率和需活检男性比例。

关键影像表现/征象

  • 病灶<10 mm时超声不可见比例为42.7%,病灶≥10 mm时为20.0%(p<0.001)。
  • 病灶<10 mm时饱和活检和系统活检的附加价值分别为11.1%和17.1%,病灶≥10 mm时分别为4.2%和6.3%。

诊断标准与关键数值

  • 临床显著前列腺癌总检出率为35%(110/313)。
  • 以PSA密度>0.15 ng/mL/mL为阈值用于MRI不可疑时,需活检男性减少14%(44/313)。

临床应用与阅片要点

  • 病灶<10 mm时超声更常不可见,且饱和活检和系统活检的附加价值更高,确定活检策略时应考虑病灶大小。
  • MRI不可疑时使用PSA密度>0.15 ng/mL/mL作为阈值可减少需活检的男性人数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate whether the detection of clinically significant prostate cancer (csPCa) and the added value of focal saturation biopsy and systematic biopsy (SBx) differ according to index lesion size, and to compare the current guidelines for csPCa detection.

METHODS: This retrospective study included consecutive men who underwent MRI and subsequent SBx and MRI-targeted biopsy (TBx) for a suspicious lesion between April 2019 and February 2020. Lesion visibility on transrectal ultrasound (US) and added value of focal saturation biopsy and SBx were compared according to index lesion size using chi-square and McNemar tests. csPCa detection rates and the proportion of biopsy-indicated men were compared among four biopsy strategies based on current guidelines.

RESULTS: Of 313 men evaluated (median age, 65; interquartile range 60‒71), csPCa was detected in 110 (35%). In lesions < 10 mm, greater US invisibility (42.7% of lesions < 10 mm versus 20.0% of lesions ≥ 10 mm; p < 0.001) and higher added value of focal saturation biopsy and SBx (11.1% and 17.1% in lesions < 10 mm versus 4.2% and 6.3% in lesions ≥ 10 mm) were observed, compared with lesions ≥ 10 mm. Consideration of prostate-specific antigen (PSA) density > 0.15 ng/mL/mL as a cutoff in unsuspicious MRI led to a 14% reduction (44/313) in men who needed biopsy.

CONCLUSION: Determination of the biopsy strategy in terms of the need for focal saturation biopsy or SBx should be made considering lesion size. The use of PSA density in non-suspicious MRI can lead to a reduction in biopsy-indicated men.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Park MY, Park KJ, Lim B, et al. Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway. Abdom Radiol (NY). 2020. PMID: 32737545. doi:10.1007/s00261-020-02667-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。